DNA REPAIR DRUGS MARKET ANALYSIS

Dna Repair Drugs Market Size and Trends

Global DNA repair drugs market is estimated to be valued at USD 7.10 Bn in 2024 and is expected to reach USD 16.80 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13.1% from 2024 to 2031.

To learn more about this report, request sample copy

Global DNA repair drugs market is expected to witness robust growth over the forecast period due to factors such as increasing prevalence of cancer burden worldwide and rising demand for targeted therapies to repair defects in DNA damage response pathways in cancer cells. Furthermore, ongoing research activities in fields like CRISPR-based technologies for precise and customized DNA repair approaches can drive the market growth. However, lengthy drug development cycles and stringent regulations for these drugs can hamper the market growth. Partnerships between private and public entities for research funding and new product launches can drive the market growth.

Increasing Prevalence of Cancer

Rising burden of cancer can drive the market growth. In 2020, an estimated 19.3 million new cancer cases and 10 million cancer deaths occurred worldwide. The five-year prevalence of cancer for the same year was estimated to be over 43.8 million people. If preventive measures are not taken or medical breakthroughs are not made, the global cancer burden will increase in the future due to rapidly aging populations and adoption of cancer-causing lifestyle choices such as smoking. Cancer develops due to damage caused to the DNA of healthy cells, either due to external factors like tobacco use, chemicals, radiation or due to internal factors like inherited genetic mutations, hormones, or immune conditions. When DNA damage occurs, it is vital that DNA repair mechanisms function properly in the cells to repair DNA and prevent uncontrolled cell growth. However, as cancer incidence rises worldwide, more and more people are developing DNA mutations that DNA repair mechanisms are unable to fix, thus, resulting in cancer. This has created a massive clinical need for drugs that can specifically target DNA repair pathways and help repair DNA damage, thus, preventing cancer onset or progression. Pharmaceutical companies are ramping up research efforts to develop innovative DNA repair drugs to address this unmet need. For instance,  according to the data published by the ICMR-National Cancer Registry Programme, in December 2022, 1,461,427 cancer cases were reported in India, as compared to 1,426,447 cases in 2021.  Rising cancer incidence rate boosts demand for DNA repair medications, and this can drive the market growth. Growing industry focus on the creation and research of innovative cancer treatment medications can also drive the market growth. In August 2021, Artios Pharma successfully raised EUR 129 million in a Series C fundraising round to develop cancer treatments that specifically target the cell's DNA repair machinery.

Advances in Genomics and Precision Oncology

The field of oncology is undergoing a revolution due to advances in genomics and precision medicine approaches. Next generation sequencing technologies enable comprehensive molecular profiling of tumor DNA and RNA to identify genetic alterations and mutations associated with specific cancer types. This provides deeper insights into tumor biology and elucidate the role of defective DNA repair mechanisms in cancer development. Large scale cancer genome profiling efforts have uncovered a large number of genetic mutations affecting DNA repair genes like BRCA1, BRCA2, ATM, and others across many different cancer types. By uncovering the specific DNA repair defects present in a patient’s tumor, precision oncology aims to match targeted therapies to these defects. Several DNA repair inhibitors are already being tested in clinical trials, particularly for cancers with homogeneous DNA repair defects like BRCA mutations in breast and ovarian cancer. As genomic profiling becomes more widespread, there will be increase in number of patients identified with DNA repair pathway alterations who may benefit from these therapies. Pharmaceutical companies are tremendously encouraged by the initial promising results with DNA repair drugs in trials.